Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 2/20 | 0.30 |
| ▸ | CD40 | P25942 | 1/20 | 0.30 |
| ▸ | CD40LG | P29965 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22910857 | 0.92 | ROCK2 (0.37) | MGLLROCK2PDK2TTK | |
| SCHEMBL22910874 | 0.91 | TLR9 (0.35) | MGLLTLR9TLR8TLR7ROCK2 | |
| SCHEMBL16759731 | 0.91 | TLR9 (0.35) | MGLLTLR9TLR8TLR7ROCK2 | |
| SCHEMBL22910574 | 0.90 | MGLL (0.32) | MGLLTLR9TLR8TLR7ROCK2 | |
| SCHEMBL22911144 | 0.89 | MGLL (0.37) | MGLLMAPTPDK2 | |
| SCHEMBL22910871 | 0.88 | LRRK2 (0.34) | — | |
| SCHEMBL22911021 | 0.87 | PDK2 (0.36) | ROCK2PDK2TTK | |
| SCHEMBL22910868 | 0.87 | ATXN2 (0.37) | MGLLROCK2 | |
| SCHEMBL22911075 | 0.86 | LRRK2 (0.30) | — | |
| SCHEMBL22911099 | 0.84 | FASN (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | MGLL 3367/4885TLR9 3544/4885TLR8 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.